CDT Equity (CDT) vs Medicus Pharma (MDCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Medicus Pharma is the larger company by market cap ($138,068 vs $29,108), about 4.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDT | MDCX |
|---|---|---|
| Share price | $0.718 | $0.0921 |
| Market cap | $29.11K | $138.07K |
| 1-day change | -10.25% | -9.62% |
| YTD return | — | -93.98% |
| 1-year return | — | -96.33% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $90,812.50 | $-119.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28,400.00 | $139.00 |
| 52-week low | $0.70 | $0.084 |
| Distance from 52-week high | -100.00% | -99.93% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +4785.99% |
| Average volume | 188.27K | 92.96K |
| Shares outstanding | 40.54K | 1.50M |
| Employees | 4 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medicus Pharma is about 4.7 times larger than CDT Equity by market value ($138.07K vs $29.11K).
About CDT Equity
CDT stock →CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
CDT vs MDCX FAQ
Which is bigger, CDT Equity or Medicus Pharma?
Medicus Pharma (MDCX) is larger, with a market capitalization of $138.07K compared with $29.11K for CDT Equity (CDT).
Are CDT Equity and Medicus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.